Show simple item record

dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorAthanasiades, A.en
dc.contributor.authorKalogera-Fountzila, Annaen
dc.contributor.authorSamantas, E.en
dc.contributor.authorBacoyiannis, Charalambosen
dc.contributor.authorNicolaou, A.en
dc.contributor.authorDombros, N.en
dc.contributor.authorBriassoulis, E. Chen
dc.contributor.authorDinopoulou, M.en
dc.contributor.authorStathopoulos, G. P.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorKosmidis, Paraskevas A.en
dc.contributor.authorDaniilidis, J.en
dc.creatorFountzilas, Georgeen
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorAthanasiades, A.en
dc.creatorKalogera-Fountzila, Annaen
dc.creatorSamantas, E.en
dc.creatorBacoyiannis, Charalambosen
dc.creatorNicolaou, A.en
dc.creatorDombros, N.en
dc.creatorBriassoulis, E. Chen
dc.creatorDinopoulou, M.en
dc.creatorStathopoulos, G. P.en
dc.creatorPavlidis, Nicholasen
dc.creatorKosmidis, Paraskevas A.en
dc.creatorDaniilidis, J.en
dc.date.accessioned2018-06-22T09:53:07Z
dc.date.available2018-06-22T09:53:07Z
dc.date.issued1997
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41666
dc.description.abstractBackground: Paclitaxel has been demonstrated to have significant activity in recurrent or metastatic head and neck cancer (HNC). In addition, the combination of paclitaxel and cisplatin is active in untreated patients with inoperable HNC. Substitution of carboplatin for cisplatin allows the treatment to be delivered on an outpatient basis. Purpose of the study: To evaluate the activity and toxicity of the combination of paclitaxel by three- hour infusion and carboplatin as first-line chemotherapy in patients with recurrent or metastatic HNC. Patients and methods: From March 1994 until August 1996, 49 patients with recurrent or metastatic HNC were treated with paclitaxel (200 mg/m2, by three-hour infusion) followed by carboplatin at an AUC of 7 mg min/ml, every four weeks. G-CSF was administered prophylactically on days 2 to 12 of each cycle. There were 41 men and 8 women with a median age of 57 years (range 23-73). The majority of the patients were symptomatic and they had recurrent disease locoregionally. Fourteen patients had nasopharyngeal cancer (NPC) and 35 had squamous cell cancers of other areas of the head and neck region (non-NPC). Results: At the completion of treatment, two patients with NPC demonstrated complete and six partial responses for an overall response rate of 57% (95% CI 29%-82%). Among patients with non-NPC, the response rate was 23% (95% CI 97%-37%). After a median follow up period of 15 months, the median time to progression was 4.3 months in the non-NPC group and 16.5 months in the NPC group. At the time of the analysis, median survival had not been reached in NPC while it was 7.3 months in non-NPC patients. Grade 3-4 toxicities included anemia (2%) and leukopenia, thrombocytopenia, stomatitis, nausea/vomiting and diarrhea (4% each). Conclusions: The combination of paclitaxel and carboplatin appears to be well tolerated but only moderately active in patients with advanced non- NPC of the head and neck region. However, its activity appears promising in NPC and deserves further investigation.en
dc.language.isoengen
dc.sourceAnnals of Oncologyen
dc.subjectArticleen
dc.subjectCisplatinen
dc.subjectHumanen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectFemaleen
dc.subjectMiddle ageden
dc.subjectAdvanced canceren
dc.subjectCancer survivalen
dc.subjectChemotherapyen
dc.subjectComputer assisted tomographyen
dc.subjectPriority journalen
dc.subjectAnemiaen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectClinical articleen
dc.subjectClinical trialen
dc.subjectLeukopeniaen
dc.subjectNeutropeniaen
dc.subjectPhase 2 clinical trialen
dc.subjectRecombinant granulocyte colony stimulating factoren
dc.subjectStomatitisen
dc.subjectThrombocytopeniaen
dc.subjectArea under the curveen
dc.subjectGranulocyte colony stimulating factoren
dc.subjectTreatment outcomeen
dc.subjectGranulocytopeniaen
dc.subjectMaleen
dc.subjectCarboplatinen
dc.subjectBlood cell counten
dc.subjectGastrointestinal symptomen
dc.subjectSubcutaneous drug administrationen
dc.subjectPaclitaxelen
dc.subjectHead and neck neoplasmsen
dc.subjectHead and neck canceren
dc.subjectHead and neck carcinomaen
dc.subjectInfusionen
dc.subjectNasopharyngeal canceren
dc.subjectNasopharyngeal neoplasmsen
dc.subjectNasopharynx carcinomaen
dc.titlePaclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck: A phase II study conducted by the Hellenic Cooperative Oncology Groupen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1023/A:1008279503428
dc.description.volume8
dc.description.issue5
dc.description.startingpage451
dc.description.endingpage455
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidKalogera-Fountzila, Anna [0000-0002-6801-3129]
dc.gnosis.orcid0000-0002-2195-9961|0000-0002-6801-3129


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record